论文部分内容阅读
目的通过舒洛地特联合替米沙坦对2型糖尿病视网膜病变(diabetic retinopathy,DR)减少眼底微动脉瘤、延缓DR进展速度有效性的观察,评价舒洛地特和替米沙坦联合应用对DR的疗效。方法 162例DR患者随机分为三组,替米沙坦组、舒洛地特组和联合治疗组,所有患者随访6个月,随访过程中定期检查眼底,空腹血糖、糖化血红蛋白、谷丙转氨酶、谷草转氨酶、纤维蛋白原。结果三组患者眼底微动脉瘤治疗后较治疗前均明显较少,差异有统计学意义(P<0.05),治疗后三组间患者眼底微动脉瘤比较,差异无统计学意义(P>0.05),联合治疗组与替米沙坦组、舒洛地特组相比,可延缓DR增殖型进展速度,差异有统计学意义(P<0.05)。结论舒洛地特联合替米沙坦治疗DR能有效减少眼底微动脉瘤、延缓DR进展速度,疗效优于单一治疗组。
Objective To evaluate the effectiveness of sulodentid and telmisartan in combination with telmisartan in reducing the rate of retinal micro-aneurysms and slowing the progression of DR in type 2 diabetic retinopathy (DR) The efficacy of DR. Methods 162 patients with DR were randomly divided into three groups, telmisartan group, sulodentide group and combination therapy group. All patients were followed up for 6 months. During the follow-up period, fundus examination, fasting blood glucose, glycosylated hemoglobin, alanine aminotransferase , Aspartate aminotransferase, fibrinogen. Results The fundus aneurysms in three groups were significantly less after treatment than those before treatment (P <0.05). There was no significant difference in the fundus aneurysm between the three groups after treatment (P> 0.05 ), Combined treatment group and telmisartan group, compared with sulodexide can delay the rate of progress of DR proliferation, the difference was statistically significant (P <0.05). Conclusion The combination of sulodentid and telmisartan in the treatment of DR can effectively reduce the fundus aneurysm and delay the progression of DR, which is superior to single treatment group.